Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis

Table 2

Sensitivity and specificity of anti-MCV antibodies, anti-CCP antibodies, and RF in RA patients.

Test	Sensitivity; (95% CI)	Specificity; (95% CI)	Positive predictive value; (95% CI)	Negative predictive value; (95% CI)	Odd ratio
Anti-MCV	0.72 (65.3–78.6)	0.87 (82.8–90.2)	0.78 ( 71.8–80.4)	0.83 (79.9–86.5)	0.726
Anti-CCP	0.52 (49.5–63.2)	0.97 (91.7–96.8)	0.93 (78.7–90.9)	0.76 (71.9–79.7)	4.2
RF	0.57 (52.7–60.3)	0.94 (88.9–92.6)	0.87 (76.5–86.6)	0.78 (74.3–82.8)	1.9

Anti-MCV: mutated citrullinated vimentin, anti-CCP: anti-cyclic citrullinated peptide, RF: Rheumatoid factor, and RA: rheumatoid arthritis.